TTOO - T2 Biosystems affirms plans to add Candida Auris fungus detection to test panel

2023-03-23 10:12:12 ET

• T2 Biosystems ( NASDAQ: TTOO ) confirmed its plans to add detection of fungal pathogen Candida auris to its FDA-cleared and CE marked T2Candida Panel.
• A rare and often deadly fungal species is spreading across the U.S. The fungus, a type of yeast called Candida auris, first detected about 15 years ago in Japan, has made a comeback in the U.S., accounting for at least 2,377 cases in 2022, according to the Centers for Disease Control and Prevention (CDC). The fungus is often multidrug-resistant.
• "With prior support from the CDC, we have completed feasibility and early development of a diagnostic test to detect the Candida auris pathogen directly-from-blood and we plan to add this test to our FDA-cleared T2Candida Panel," said T2 Biosystems' Chairman and CEO John Sperzel.
• Sperzel added that the company is also exploring partnerships to accelerate the path toward commercialization.
• The company noted that the T2Candida panel detects sepsis-causing fungal pathogens directly from whole blood, without the need to wait for days for a positive blood culture.

For further details see: